JAZZ News and Press, Jazz Pharmaceuticals plc From 01/09/23

Summary Today, we circle back on Zymeworks Inc. and update our analysis to account for recent events. A recent license agreement has left the company flush with cash as it continues to advance its lead candidate. An investment analysis follows in the paragraphs below. ...

Jazz Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire DUBLIN , Jan. 3, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the 41 st ...

Summary Axsome has one pending approval and two pending NDAs coming up in 2023. They are adequately funded, if not very strongly. I will hold on to my post-profit shares for one more year. I have been covering Axsome Therapeutics ( AXSM ) since 2020, and have been cons...

This has not been the year of marijuana stocks. Although that's not too surprising, as equity markets have been southbound, the industry has substantially lagged the broader market. Thankfully, there is hope for cannabis investors. While estimates vary, analysts have predicted that the pot indust...

Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab PR Newswire Follows positive top-line clinical data readout from HERIZON-BTC-01 pivotal trial in biliary tract cancers DUBLIN and VANCOUVER, BC , ...

Jazz Pharmaceuticals ( NASDAQ: JAZZ ) traded higher in the pre-market Friday after Goldman Sachs upgraded the Ireland-based biopharma to Buy from Neutral, citing a favorable outlook for its operating margin performance. The upgrade comes weeks after Avadel Pharmaceuticals ( AVDL )...

Summary Avadel's LUMRYZ in treatment of cataplexy in adults with narcolepsy received tentative FDA approval, temporarily blocked by a patent owned by Jazz Pharmaceuticals. The situation creates a David vs. Goliath match-up of great importance for both companies. Jazz is taking the f...

Summary Lumyrz overhang now removed with competitor ordered to delist patent from FDA's Orange Book. The treatment has potential to create a remedial breakthrough in narcolepsy. We rate AVDL a buy now with the overhang removed, with far more clarity on the route to full FDA approval...

The Daily Hit is a recap of cannabis business news for Dec. 5, 2022. ON THE SITE Biden Signs Historic Marijuana Research Bill, Lawmakers Push Additional Measures After months of policy debates and trading barbs on Capitol Hill, a U.S. president has finally sent through the first p...

Ireland-based Jazz Pharmaceuticals (Nasdaq: JAZZ) announced that its anti-epileptic over-the-counter cannabis drug, Epidiolex , has been found to be effective “across age groups,” not just young children, according to a survey of caregivers presented recently at a gather...